d1e30690_dic_NECT___Inclusion_completed__Cancer_type
[Title] Safety and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study with randomised phase II expansion component [Country] FI [Cancer type] 
Prostate cancer
Nordic NECT - Inclusion completed
Cancer type